EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PDE3A as a Therapeutic Target for the Modulation of Compartmentalised Cyclic Nucleotide-Dependent Signalling

Swaroop Ranjan Pati, Anastasiia Sholokh iD, Enno Klussmann iD

Cells · 2025

DOI: 10.3390/cells14110771 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Swaroop Ranjan Pati und 2 weiteren Autor:innen. Beteiligte Einrichtung: Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 3, Signal Transduction, Cyclic AMP. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Else Kröner-Fresenius-Stiftung, Federal Ministry of Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphodiesterase 3A (PDE3A) hydrolyses cAMP, adjusting cAMP signalling pathways with temporal and spatial accuracy. PDE3A contributes to the control of cAMP in several cellular compartments, including the plasma membrane, the cytosol, or membrane-limited organelles such as the nucleus and the sarcoplasmic reticulum. Through this ability and its expression in various cell types, it regulates a variety of cellular processes like contractility of muscle cells, gene expression, differentiation and proliferation. Dysregulated cAMP signalling causes or is associated with diseases. The therapeutic potential of PDE3A is, however, limited by the lack of specific modulators. Emerging approaches to targeting PDE3A centre on specifically addressing its catalytic domain or its cellular localisation. This review highlights the growing knowledge of PDE3A’s functions in cellular signalling and therapeutic opportunities, opening the door to more fully utilise its potential for the treatment of disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic Nucleotide Phosphodiesterases, Type 3Signal TransductionCyclic AMPHumansAnimalsMolecular Targeted TherapyPhosphodiesterase 3 Inhibitors

Stichwörter der Autor:innen

cAMPcompartmentalisationphosphodiesterase 3A

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 3Cyclic AMPPhosphodiesterase 3 Inhibitors

Autor:innen und Institutionen

  • Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.
  • Faculty of Biology, Chemistry, Pharmacy, Freie Universität Berlin, 14195 Berlin, Germany.
  • DZHK (German Centre for Cardiovascular Research), Partner Site, 10785 Berlin, Germany.

ORCID-Profile: Anastasiia Sholokh, Enno Klussmann

Förderung

  • Deutsche Forschungsgemeinschaft
  • Else Kröner-Fresenius-Stiftung
  • Federal Ministry of Education and Research
  • Federal Ministry for Education and Science

Zitieren

APA

Pati, S. R., Sholokh, A., & Klussmann, E. (2025). PDE3A as a Therapeutic Target for the Modulation of Compartmentalised Cyclic Nucleotide-Dependent Signalling. Cells. https://doi.org/10.3390/cells14110771

Vancouver

Pati SR, Sholokh A, Klussmann E. PDE3A as a Therapeutic Target for the Modulation of Compartmentalised Cyclic Nucleotide-Dependent Signalling. Cells. 2025. doi:10.3390/cells14110771

BibTeX
@article{Pati2025,
  author = {Pati, Swaroop Ranjan and Sholokh, Anastasiia and Klussmann, Enno},
  title = {PDE3A as a Therapeutic Target for the Modulation of Compartmentalised Cyclic Nucleotide-Dependent Signalling},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14110771}
}
Kostenlos starten →